Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

IDEXX Laboratories (IDXX)

NASDAQ: IDXX · Veterinary Diagnostics · Westbrook, ME

Our rating: Neutral

Neutral reaffirmed at $672.04, moderate conviction, November 3, 2026.

Breaks if: The neutral call turns cautious if revenue growth decelerates below 7% year-over-year for two consecutive reported quarters while the net margin slips below 22% — that combination would signal the franchise is losing pricing or volume leverage without a commensurate valuation reset. It turns positive if revenue growth re-accelerates above 15% for two straight quarters and the free-cash-flow yield expands above 2.5%, suggesting the multiple is starting to earn its keep rather than merely hold its ground.

Key figures

Market value$53.3B
Revenue, last 12 months$4.7B
Net income, last 12 months$1.2B
Free cash flow, last 12 months$1.3B
Price to earnings45.1×
Free cash flow yield2.4%
Dividend yield0.0%
Operating margin32.3%
Return on equity68.9%
Beta to the S&P 5000.89
Volatility, annualized38.2%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$1.2B9.9%$4.01$421M
June 30, 2026$1.2B9.7%$4.27$323M
March 31, 2026$1.1B14.3%$3.47$234M
December 31, 2025$1.1B14.3%$3.09$326M
September 30, 2025$1.1B13.3%$3.40$371M
June 30, 2025$1.1B10.6%$3.63$152M
March 31, 2025$998M3.6%$2.96$208M
December 31, 2024$954M5.8%$2.62$233M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

13 ledger entries and 38 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.